Research
Late-Life Depression: Determining Optimal Ketamine Doses
This study evaluates the effectiveness of different doses of a single ketamine infusion for late-life treatment-resistant depression (LL-TRD) in veterans. It employs a triple-blind design to compare the impact of various ketamine doses to midazolam, focusing on depression improvement measured by the Montgomery-Asberg Depression Rating Scale. The research also explores the safety, tolerability, and lasting effects of ketamine over a four-week period.
Studies & Research
Ketamine in Major Depressive and Bipolar Disorder: A Meta-Analysis Review
Ketamine's Immediate and Extended Impact on Suicidality: A Medical Inpatient Study
Ketamine's Role in Reducing Alcohol Consumption: Targeting Maladaptive Reward Memories
Exploring Ketamine's Impact on Anxious Depression: MRI Insights into Brain Activity and Antidepressant Effects
Ketamine as a Dual Treatment for Depression and Alcohol Dependence: A Groundbreaking Study
Ketamine's Potential in Rapidly Reducing Suicidal Ideation: A Comparative Study
Late-Life Depression: Determining Optimal Ketamine Doses
Disclaimers
Financing Disclaimer: We offer two financing options for the Uplift Momentum Protocol™ (medical procedure): $325/month for 12 months, with a total cost of $3,900, no down payment, 0% APR, or $1,000 down payment and $237/month for 12 months, with a total cost of $3,844, 0% APR. Approval for both plans is based on internal criteria, including bank account history and a soft credit pull. Payments may be auto-withdrawn monthly. Both plans are subject to a $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement is allowed. Governed by California law and AAA arbitration rules
Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.
Questions?
(310) 280-4440
care@ketamineuplift.com
4640 Admiralty Way
Suite 718A
Marina del Rey, CA 90292
© 2024 Ketamine Uplift | Terms & Conditions | Privacy Policy | HIPAA Policy
Research
Late-Life Depression: Determining Optimal Ketamine Doses
This study evaluates the effectiveness of different doses of a single ketamine infusion for late-life treatment-resistant depression (LL-TRD) in veterans. It employs a triple-blind design to compare the impact of various ketamine doses to midazolam, focusing on depression improvement measured by the Montgomery-Asberg Depression Rating Scale. The research also explores the safety, tolerability, and lasting effects of ketamine over a four-week period.
Studies & Research
Ketamine in Major Depressive and Bipolar Disorder: A Meta-Analysis Review
Ketamine's Immediate and Extended Impact on Suicidality: A Medical Inpatient Study
Ketamine's Role in Reducing Alcohol Consumption: Targeting Maladaptive Reward Memories
Exploring Ketamine's Impact on Anxious Depression: MRI Insights into Brain Activity and Antidepressant Effects
Ketamine as a Dual Treatment for Depression and Alcohol Dependence: A Groundbreaking Study
Ketamine's Potential in Rapidly Reducing Suicidal Ideation: A Comparative Study
Late-Life Depression: Determining Optimal Ketamine Doses
Disclaimers
Financing Disclaimer: We offer two financing options for the Uplift Momentum Protocol™ (medical procedure): $325/month for 12 months, with a total cost of $3,900, no down payment, 0% APR, or $1,000 down payment and $237/month for 12 months, with a total cost of $3,844, 0% APR. Approval for both plans is based on internal criteria, including bank account history and a soft credit pull. Payments may be auto-withdrawn monthly. Both plans are subject to a $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement is allowed. Governed by California law and AAA arbitration rules
Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.
Questions?
(310) 280-4440
care@ketamineuplift.com
4640 Admiralty Way
Suite 718A
Marina del Rey, CA 90292
© 2024 Ketamine Uplift | Terms & Conditions | Privacy Policy | HIPAA Policy